000289450 001__ 289450
000289450 005__ 20250819104912.0
000289450 0247_ $$2doi$$a10.1016/S2468-1253(23)00357-6
000289450 0247_ $$2pmid$$apmid:38604200
000289450 0247_ $$2ISSN$$a2468-1253
000289450 0247_ $$2ISSN$$a2468-1156
000289450 0247_ $$2altmetric$$aaltmetric:161675932
000289450 037__ $$aDKFZ-2024-00772
000289450 041__ $$aEnglish
000289450 082__ $$a610
000289450 1001_ $$aPorcari, Serena$$b0
000289450 245__ $$aFine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics.
000289450 260__ $$aLondon$$bElsevier$$c2024
000289450 3367_ $$2DRIVER$$aarticle
000289450 3367_ $$2DataCite$$aOutput Types/Journal article
000289450 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1713269084_20785$$xReview Article
000289450 3367_ $$2BibTeX$$aARTICLE
000289450 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289450 3367_ $$00$$2EndNote$$aJournal Article
000289450 520__ $$aThe gut microbiome is acknowledged as a key determinant of human health, and technological progress in the past two decades has enabled the deciphering of its composition and functions and its role in human disorders. Therefore, manipulation of the gut microbiome has emerged as a promising therapeutic option for communicable and non-communicable disorders. Full exploitation of current therapeutic microbiome modulators (including probiotics, prebiotics, and faecal microbiota transplantation) is hindered by several factors, including poor precision, regulatory and safety issues, and the impossibility of providing reproducible and targeted treatments. Artificial microbiota therapeutics (which include a wide range of products, such as microbiota consortia, bacteriophages, bacterial metabolites, and engineered probiotics) have appeared as an evolution of current microbiota modulators, as they promise safe and reproducible effects, with variable levels of precision via different pathways. We describe the landscape of artificial microbiome therapeutics, from those already on the market to those still in the pipeline, and outline the major challenges for positioning these therapeutics in clinical practice.
000289450 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000289450 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289450 650_7 $$2NLM Chemicals$$aPrebiotics
000289450 650_2 $$2MeSH$$aHumans
000289450 650_2 $$2MeSH$$aMicrobiota
000289450 650_2 $$2MeSH$$aProbiotics: therapeutic use
000289450 650_2 $$2MeSH$$aPrebiotics
000289450 650_2 $$2MeSH$$aGastrointestinal Microbiome
000289450 650_2 $$2MeSH$$aFecal Microbiota Transplantation
000289450 7001_ $$aFusco, William$$b1
000289450 7001_ $$aSpivak, Igor$$b2
000289450 7001_ $$aFiorani, Marcello$$b3
000289450 7001_ $$aGasbarrini, Antonio$$b4
000289450 7001_ $$0P:(DE-He78)725ad944da4e1ea60389fe9dbbed2c7c$$aElinav, Eran$$b5$$udkfz
000289450 7001_ $$aCammarota, Giovanni$$b6
000289450 7001_ $$aIaniro, Gianluca$$b7
000289450 773__ $$0PERI:(DE-600)2874542-5$$a10.1016/S2468-1253(23)00357-6$$gVol. 9, no. 5, p. 460 - 475$$n5$$p460 - 475$$tThe lancet / Gastroenterology & Hepatology$$v9$$x2468-1253$$y2024
000289450 8564_ $$uhttps://inrepo02.dkfz.de/record/289450/files/1-s2.0-S2468125323003576-main.pdf
000289450 8564_ $$uhttps://inrepo02.dkfz.de/record/289450/files/1-s2.0-S2468125323003576-main.pdf?subformat=pdfa$$xpdfa
000289450 909CO $$ooai:inrepo02.dkfz.de:289450$$pVDB
000289450 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)725ad944da4e1ea60389fe9dbbed2c7c$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000289450 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000289450 9141_ $$y2024
000289450 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET GASTROENTEROL : 2022$$d2023-08-24
000289450 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000289450 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000289450 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000289450 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000289450 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000289450 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000289450 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-24
000289450 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bLANCET GASTROENTEROL : 2022$$d2023-08-24
000289450 9201_ $$0I:(DE-He78)F220-20160331$$kF220$$lMikrobiom und Krebs$$x0
000289450 9201_ $$0I:(DE-He78)D480-20160331$$kD480$$lMikrobiom und Krebs$$x1
000289450 980__ $$ajournal
000289450 980__ $$aVDB
000289450 980__ $$aI:(DE-He78)F220-20160331
000289450 980__ $$aI:(DE-He78)D480-20160331
000289450 980__ $$aUNRESTRICTED